105 related articles for article (PubMed ID: 1850558)
1. Angiotensin converting enzyme inhibitors potentiate the vasorelaxant effect of fibrinogen-derived peptide 6A.
Saldeen K; Lawson DL; Mehta JL
Thromb Res; 1991 Jan; 61(1):81-5. PubMed ID: 1850558
[No Abstract] [Full Text] [Related]
2. Inhibition of angiotensin-converting enzyme in human hand veins.
Chalon S; Bedarida GV; Moreno H; Tejura B; Urae A; Hoffman BB; Blaschke TF
Clin Pharmacol Ther; 1999 Jan; 65(1):58-65. PubMed ID: 9951431
[TBL] [Abstract][Full Text] [Related]
3. Direct angiotensin converting enzyme inhibitor-mediated venodilation.
Zarnke KB; Feldman RD
Clin Pharmacol Ther; 1996 May; 59(5):559-68. PubMed ID: 8646827
[TBL] [Abstract][Full Text] [Related]
4. Impairment of endothelium-dependent relaxation of rat aortas by homocysteine thiolactone and attenuation by captopril.
Liu YH; You Y; Song T; Wu SJ; Liu LY
J Cardiovasc Pharmacol; 2007 Aug; 50(2):155-61. PubMed ID: 17703131
[TBL] [Abstract][Full Text] [Related]
5. Effect of captopril on acetylcholine-induced relaxation in the presence of nitroglycerin tolerance in isolated rabbit aorta.
Moroi M; Akatsuka N; Fukazawa M; Ishikawa M; Aikawa J; Namiki A; Yamaguchi T
J Vasc Res; 1995; 32(5):347-52. PubMed ID: 7578803
[TBL] [Abstract][Full Text] [Related]
6. Replacement of L-Lys by D-Lys(NH2) in peptide Ala-Arg-Pro-Ala-Lys (peptide 6A) increases its coronary blood flow-promoting properties.
Saldeen TG; Nichols WW; Saldeen K; Wallin R; Mehta JL
J Cardiovasc Pharmacol; 1994 Jan; 23(1):103-6. PubMed ID: 7511720
[TBL] [Abstract][Full Text] [Related]
7. Endothelium-dependent vasodilation is augmented by angiotensin converting enzyme inhibitors in healthy volunteers.
Nakamura M; Funakoshi T; Yoshida H; Arakawa N; Suzuki T; Hiramori K
J Cardiovasc Pharmacol; 1992 Dec; 20(6):949-54. PubMed ID: 1282598
[TBL] [Abstract][Full Text] [Related]
8. Renal hemodynamic effects of nonhypotensive doses of angiotensin-converting enzyme inhibitors in hypertension and heart failure rats.
Nelissen-Vrancken HJ; Struijker-Boudier HA; Smits JF
J Cardiovasc Pharmacol; 1992 Feb; 19(2):163-8. PubMed ID: 1376783
[TBL] [Abstract][Full Text] [Related]
9. Angiotensin converting enzyme dependent and non-dependent effects of a fibrinogen-derived pentapeptide on microvascular permeability in rat skin.
Eriksson M; Gerdin B; Saldeen T
Ups J Med Sci; 1983; 88(2):95-101. PubMed ID: 6316608
[TBL] [Abstract][Full Text] [Related]
10. The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels.
van Onzenoort HA; Bussink M; Menheere PP; van Mook WN; van der Kuy PH
Pharm World Sci; 2006 Jun; 28(3):131-4. PubMed ID: 17004021
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological profiles of CS-622, a novel angiotensin converting enzyme inhibitor.
Oizumi K; Koike H; Sada T; Miyamoto M; Nishino H; Matsushita Y; Iijima Y; Yanagisawa H
Jpn J Pharmacol; 1988 Nov; 48(3):349-56. PubMed ID: 2851680
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of antiarrhythmic activity of captopril and enalaprilat in experimental cardiac arrhythmias in rabbits. Part II.
Dzielska-Olczak M; Polakowski P
Pol J Pharmacol; 1998; 50(3):233-7. PubMed ID: 9861631
[TBL] [Abstract][Full Text] [Related]
13. Studies on the interactions between the angiotensin converting enzyme inhibitor enalaprilat and calcium antagonists in rats.
Marwood JF
J Hypertens; 1996 Jan; 14(1):123-9. PubMed ID: 12013484
[TBL] [Abstract][Full Text] [Related]
14. Carboxyl-terminal tripeptidyl hydrolysis of substance P by purified rabbit lung angiotensin-converting enzyme and the potentiation of substance P activity in vivo by captopril and MK-422.
Cascieri MA; Bull HG; Mumford RA; Patchett AA; Thornberry NA; Liang T
Mol Pharmacol; 1984 Mar; 25(2):287-93. PubMed ID: 6199659
[TBL] [Abstract][Full Text] [Related]
15. Fosinopril and zofenopril, two angiotensin-converting enzyme (ACE) inhibitors, potentiate the anticonvulsant activity of antiepileptic drugs against audiogenic seizures in DBA/2 mice.
Sarro GD; Paola ED; Gratteri S; Gareri P; Rispoli V; Siniscalchi A; Tripepi G; Gallelli L; Citraro R; Russo E
Pharmacol Res; 2012 Mar; 65(3):285-96. PubMed ID: 22107891
[TBL] [Abstract][Full Text] [Related]
16. The effects of bradykinin and the ischemic isolated rat heart.
Tio RA; van Gilst WH; Rett K; Wolters K; Dietze GJ; Wesseling H
Horm Metab Res Suppl; 1990; 22():85-9. PubMed ID: 2167866
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide-mediated vasorelaxation effects of anti-angiotensin I-converting enzyme (ACE) peptide from Styela clava flesh tissue and its anti-hypertensive effect in spontaneously hypertensive rats.
Ko SC; Kim DG; Han CH; Lee YJ; Lee JK; Byun HG; Lee SC; Park SJ; Lee DH; Jeon YJ
Food Chem; 2012 Sep; 134(2):1141-5. PubMed ID: 23107740
[TBL] [Abstract][Full Text] [Related]
18. Effect of estrogen and angiotensin-converting enzyme inhibitor on vascular remodeling in ovariectomized spontaneously hypertensive rats.
García MP; Giménez J; Serna M; Salom MG; Bonacasa B; Carbonell LF; Quesada T; Hernández I
Menopause; 2006; 13(3):397-403. PubMed ID: 16735936
[TBL] [Abstract][Full Text] [Related]
19. Nitric oxide donors and angiotensin-converting enzyme inhibitors act in concert to inhibit human angiotensin-converting enzyme activity and platelet aggregation in vitro.
Persson K; Whiss PA; Nyhlén K; Jacobsson-Strier M; Glindell M; Andersson RG
Eur J Pharmacol; 2000 Oct; 406(1):15-23. PubMed ID: 11011027
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-converting enzyme inhibitors. Mercaptan, carboxyalkyl dipeptide, and phosphinic acid inhibitors incorporating 4-substituted prolines.
Krapcho J; Turk C; Cushman DW; Powell JR; DeForrest JM; Spitzmiller ER; Karanewsky DS; Duggan M; Rovnyak G; Schwartz J
J Med Chem; 1988 Jun; 31(6):1148-60. PubMed ID: 2836590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
